Download PDF
Clin Colon Rectal Surg
DOI: 10.1055/a-2771-8199
Review Article

Local Tumor Regrowth after Nonoperative Management Following Neoadjuvant Therapy for Rectal Cancer

Authors

  • Kentaro Ochiai

    1   Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • George J. Chang

    1   Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Ramy S. Behman

    1   Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Further Information
Also available at
   Permissions and Reprints

Abstract

Nonoperative management (NOM) is increasingly being adopted as a treatment strategy for rectal cancer, offering the possibility of organ preservation and avoidance of surgical morbidity for patients who achieve an excellent response to neoadjuvant therapy. However, the risk of local tumor regrowth remains a critical concern and raises questions about its impact on oncologic outcomes. Emerging data suggest that local regrowth may be associated with an increased risk of distant metastasis, highlighting the importance of timely detection and intervention. Although salvage surgery is generally feasible and effective, the technical challenges it presents and the potential implications for surgical quality necessitate careful consideration. Clinical factors such as tumor stage and treatment response may help identify patients at higher risk of regrowth, but predictive biomarkers and molecular profiling remain underexplored. As NOM continues to evolve, further studies are needed to clarify the oncologic safety, refine patient selection criteria, and develop optimal surveillance strategies to maximize the benefits while minimizing risks. This review summarizes current evidence on local tumor regrowth in the context of NOM and discusses the clinical implications of local regrowth and future directions for NOM.

Keywords

rectal cancer - nonoperative management - watch-and-wait - local regrowth - neoadjuvant therapy


Publication History

Article published online:
14 January 2026

© 2026. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Benson AB, Venook AP, Al-Hawary MM. et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (10) 1139-1167
    CrossrefPubMedSearch in Google Scholar
  • 2 Ochiai K, Bhutiani N, Ikeda A. et al. Total neoadjuvant therapy for rectal cancer: which regimens to use?. Cancers (Basel) 2024; 16 (11) 2093
    CrossrefPubMedSearch in Google Scholar
  • 3 Garcia-Aguilar J, Chow OS, Smith DD. et al; Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015; 16 (08) 957-966
    CrossrefPubMedSearch in Google Scholar
  • 4 Cercek A, Roxburgh CSD, Strombom P. et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018; 4 (06) e180071
    CrossrefPubMedSearch in Google Scholar
  • 5 Ito M, Kobayashi A, Fujita S. et al; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Urinary dysfunction after rectal cancer surgery: results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212). Eur J Surg Oncol 2018; 44 (04) 463-468
    CrossrefPubMedSearch in Google Scholar
  • 6 Saito S, Fujita S, Mizusawa J. et al; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Male sexual dysfunction after rectal cancer surgery: results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212. Eur J Surg Oncol 2016; 42 (12) 1851-1858
    CrossrefPubMedSearch in Google Scholar
  • 7 Habr-Gama A, Perez RO, Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240 (04) 711-717 , discussion 717–718
    CrossrefPubMedSearch in Google Scholar
  • 8 Gani C, Gani N, Zschaeck S. et al. Organ preservation in rectal cancer: the patients' perspective. Front Oncol 2019; 9: 318
    CrossrefPubMedSearch in Google Scholar
  • 9 Couwenberg AM, Intven MPW, Burbach JPM, Emaus MJ, van Grevenstein WMU, Verkooijen HM. Utility scores and preferences for surgical and organ-sparing approaches for treatment of intermediate and high-risk rectal cancer. Dis Colon Rectum 2018; 61 (08) 911-919
    CrossrefPubMedSearch in Google Scholar
  • 10 Dattani M, Heald RJ, Goussous G. et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis. Ann Surg 2018; 268 (06) 955-967
    CrossrefPubMedSearch in Google Scholar
  • 11 Renehan AG, Malcomson L, Emsley R. et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016; 17 (02) 174-183
    CrossrefPubMedSearch in Google Scholar
  • 12 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
    CrossrefPubMedSearch in Google Scholar
  • 13 Chadi SA, Malcomson L, Ensor J. et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2018; 3 (12) 825-836
    CrossrefPubMedSearch in Google Scholar
  • 14 Smith JJ, Strombom P, Chow OS. et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol 2019; 5 (04) e185896
    CrossrefPubMedSearch in Google Scholar
  • 15 Fernandez LM, São Julião GP, Figueiredo NL. et al; International Watch & Wait Database Consortium. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol 2021; 22 (01) 43-50
    CrossrefPubMedSearch in Google Scholar
  • 16 Lai SH, Widmar M, Monson JRT, Fleming FJ, Morris AM, Vogel JD. US Rectal Cancer Research Group. Rectal cancer watch-and-wait management: experience of 545 patients from the US Rectal Cancer Research Group. Dis Colon Rectum 2025; 68 (02) 180-189
    CrossrefPubMedSearch in Google Scholar
  • 17 Conroy T, Bosset JF, Etienne PL. et al; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (05) 702-715
    CrossrefPubMedSearch in Google Scholar
  • 18 Garcia-Aguilar J, Patil S, Gollub MJ. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022; 40 (23) 2546-2556
    CrossrefPubMedSearch in Google Scholar
  • 19 Jin J, Tang Y, Hu C. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022; 40 (15) 1681-1692
    CrossrefPubMedSearch in Google Scholar
  • 20 Bahadoer RR, Dijkstra EA, van Etten B. et al; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (01) 29-42
    CrossrefPubMedSearch in Google Scholar
  • 21 Verheij FS, Omer DM, Williams H. et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol 2024; 42 (05) 500-506
    CrossrefPubMedSearch in Google Scholar
  • 22 Bhutiani N, Ochiai K, Peacock O. et al. Risk factors for regrowth after nonoperative management for rectal cancer. Ann Surg Oncol 2025; 32 (05) 3098-3105
    CrossrefPubMedSearch in Google Scholar
  • 23 van der Stel SD, van den Berg JG, Snaebjornsson P. et al. Size and depth of residual tumor after neoadjuvant chemoradiotherapy in rectal cancer—implications for the development of new imaging modalities for response assessment. Front Oncol 2023; 13: 1209732
    CrossrefPubMedSearch in Google Scholar
  • 24 Lambregts DM, Lahaye MJ, Heijnen LA. et al. MRI and diffusion-weighted MRI to diagnose a local tumour regrowth during long-term follow-up of rectal cancer patients treated with organ preservation after chemoradiotherapy. Eur Radiol 2016; 26 (07) 2118-2125
    CrossrefPubMedSearch in Google Scholar
  • 25 Williams H, Omer DM, Thompson HM. et al; OPRA Consortium. MRI predicts residual disease and outcomes in watch-and-wait patients with rectal cancer. Radiology 2024; 312 (03) e232748
    CrossrefPubMedSearch in Google Scholar
  • 26 Nasir I, Fernandez L, Vieira P. et al. Salvage surgery for local regrowths in watch & wait—are we harming our patients by deferring the surgery?. Eur J Surg Oncol 2019; 45 (09) 1559-1566
    CrossrefPubMedSearch in Google Scholar
  • 27 Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011; 254 (01) 97-102
    CrossrefPubMedSearch in Google Scholar
  • 28 Marco MR, Zhou L, Patil S. et al; Timing of Rectal Cancer Response to Chemoradiation Consortium. Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum 2018; 61 (10) 1146-1155
    CrossrefPubMedSearch in Google Scholar
  • 29 Lefevre JH, Mineur L, Kotti S. et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 2016; 34 (31) 3773-3780
    CrossrefPubMedSearch in Google Scholar
  • 30 Rullier E, Rouanet P, Tuech JJ. et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet 2017; 390 (10093): 469-479
    CrossrefPubMedSearch in Google Scholar
  • 31 Fernandez LM, Figueiredo NL, Habr-Gama A. et al. Salvage surgery with organ preservation for patients with local regrowth after watch and wait: is it still possible?. Dis Colon Rectum 2020; 63 (08) 1053-1062
    CrossrefPubMedSearch in Google Scholar
  • 32 Fernandez LM, São Julião GP, Renehan AG. et al; International Watch & Wait Database (IWWD) Consortium. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database. Dis Colon Rectum 2023; 66 (01) 41-49
    CrossrefPubMedSearch in Google Scholar
  • 33 São Julião GP, Fernández LM, Vailati BB. et al. Local regrowth and the risk of distant metastases among patients undergoing watch-and-wait for rectal cancer: what is the best control group? Multicenter retrospective study. Dis Colon Rectum 2024; 67 (01) 73-81
    CrossrefPubMedSearch in Google Scholar
  • 34 Fernandez LM, São Julião GP, Santacruz CC. et al; International Watch & Wait Database Consortium (IWWD) and the Spanish Rectal Cancer Viking Consortium (VIKINGO), International Watch & Wait Database Consortium (IWWD) & Spanish Rectal Cancer Viking Consortium. Risks of organ preservation in rectal cancer: data from two international registries on rectal cancer. J Clin Oncol 2025; 43 (14) 1663-1672
    CrossrefPubMedSearch in Google Scholar
  • 35 Ozaki K, Kawai K, Nozawa H, Sasaki K, Murono K, Ishihara S. Development of a novel apoptosis-based tumor regression grade to assess the efficacy of preoperative chemoradiotherapy for rectal cancer: a retrospective single-center study. Int J Clin Oncol 2021; 26 (09) 1679-1688
    CrossrefPubMedSearch in Google Scholar
  • 36 Bettoni F, Masotti C, Corrêa BR. et al. The effects of neoadjuvant chemoradiation in locally advanced rectal cancer—the impact in intratumoral heterogeneity. Front Oncol 2019; 9: 974
    CrossrefPubMedSearch in Google Scholar
  • 37 Fernandez LM, Vailati BB, São Julião GP. et al. Partial responders to neoadjuvant therapy and the risk of distant metastases: longer intervals to definitive resection is not a risk factor. Dis Colon Rectum 2025; 68 (10) 1154-1161
    CrossrefPubMedSearch in Google Scholar
  • 38 Luo D, Shan Z, Liu Q. et al. The correlation between tumor size, lymph node status, distant metastases and mortality in rectal cancer patients without neoadjuvant therapy. J Cancer 2021; 12 (06) 1616-1622
    CrossrefPubMedSearch in Google Scholar
  • 39 Cotti GC, Pandini RV, Braghiroli OFM. et al. Outcomes of patients with local regrowth after nonoperative management of rectal cancer after neoadjuvant chemoradiotherapy. Dis Colon Rectum 2022; 65 (03) 333-339
    CrossrefPubMedSearch in Google Scholar
  • 40 Chandramohan A, Mittal R, Dsouza R. et al. Prognostic significance of MR identified EMVI, tumour deposits, mesorectal nodes and pelvic side wall disease in locally advanced rectal cancer. Colorectal Dis 2022; 24 (04) 428-438
    CrossrefPubMedSearch in Google Scholar
  • 41 Tan JJ, Carten RV, Babiker A, Abulafi M, Lord AC, Brown G. Prognostic importance of MRI-detected extramural venous invasion in rectal cancer: a literature review and systematic meta-analysis. Int J Radiat Oncol Biol Phys 2021; 111 (02) 385-394
    CrossrefPubMedSearch in Google Scholar
  • 42 Habr-Gama A, São Julião GP, Fernandez LM. et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think!. Dis Colon Rectum 2019; 62 (07) 802-808
    CrossrefPubMedSearch in Google Scholar
  • 43 Temmink SJD, Peeters KCMJ, Bahadoer RR. et al; International Watch & Wait Database (IWWD) Consortium. Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD). Br J Surg 2023; 110 (06) 676-684
    CrossrefPubMedSearch in Google Scholar
  • 44 Fokas E, Appelt A, Glynne-Jones R. et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol 2021; 18 (12) 805-816
    CrossrefPubMedSearch in Google Scholar
  • 45 Rosen RY, Bercz AP, Omer DM. et al. Correlation between grade of clinical response to neoadjuvant therapy for rectal cancer and oncologic outcomes in the era of watch-and-wait. Dis Colon Rectum 2025; 68 (03) 300-307
    CrossrefPubMedSearch in Google Scholar
  • 46 Alvarez JA, Shi Q, Dasari A. et al. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer 2024; 24 (01) 901
    CrossrefPubMedSearch in Google Scholar
  • 47 Watanabe J, Kagawa Y, Chida K. et al. Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial. ESMO Gastrointest Oncol 2023; 1: 9-14
    CrossrefSearch in Google Scholar
  • 48 Murahashi S, Akiyoshi T, Sano T. et al. Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer 2020; 123 (05) 803-810
    CrossrefPubMedSearch in Google Scholar
  • 49 Alden SL, Lee V, Narang AK, Meyer J, Gearhart SL, Christenson ES. Circulating tumor DNA to predict radiographic and pathologic response to total neoadjuvant therapy in locally advanced rectal cancer. Oncologist 2024; 29 (03) e414-e418
    CrossrefPubMedSearch in Google Scholar